NewcelX Ltd. announced a successful FDA Pre-IND meeting regarding its NCEL-101 candidate, establishing a clear pathway toward initiating clinical trials for the treatment of Type 1 diabetes. The company intends to use the feedback from this meeting to advance its regulatory strategy. NewcelX Ltd. is a biotechnology company focused on developing therapeutic treatments.

NewcelX Ltd. held its Annual General Shareholders’ Meeting on June 30, 2026, where shareholders approved all presented proposals. The specific details of these proposals were previously disclosed in the Notice and Invitation filed on June 5, 2026. NewcelX Ltd. is a Swiss-based company involved in the technology sector.

NewcelX Ltd. published a peer-reviewed study demonstrating the therapeutic potential of its stem cell technology platform. The company is a biotechnology company focused on developing stem cell-based therapies.